Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes

IMPORTANCE: Type 2 diabetes (T2D) and heart failure (HF) prevalence are rising in the US. Although glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve outcomes for these conditions, high out-of-pocket costs may be associated with reduced...

Descripción completa

Detalles Bibliográficos
Autores principales: Essien, Utibe R., Singh, Balvindar, Swabe, Gretchen, Johnson, Amber E., Eberly, Lauren A., Wadhera, Rishi K., Breathett, Khadijah, Vaduganathan, Muthiah, Magnani, Jared W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236237/
https://www.ncbi.nlm.nih.gov/pubmed/37261826
http://dx.doi.org/10.1001/jamanetworkopen.2023.16290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236237/
https://www.ncbi.nlm.nih.gov/pubmed/37261826
http://dx.doi.org/10.1001/jamanetworkopen.2023.16290

Ejemplares similares